ACTG 5273: Multicenter Study of Options for Second-Line Effective Combination Therapy (SELECT)
ACTG 5274: Phase IV, Open Label Strategy Trial: REMEMBER: Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens
ACTG 5282: A Randomized, Phase II Trial to Compare an HPV Test-and-Treat Strategy to a Cytology-Based Strategy for Prevention of CIN 2+ in HIV-Infected Women
ACTG 5288: Management Using the Latest Technologies in Resource-limited Settings to Optimize Combination Therapy After Viral Failure
ACTG 5300/IMPAACT 2003: Phase III, Open Label, Multi-center Trial: Protecting Households on Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients
IMPAACT 1026: Pharmacokinetic Properties of Antiretroviral Drugs During Pregnancy
IMPAACT 1077B/1077FF: Promoting Maternal and Infant Survival Everywhere (PROMISE): Breastfeeding and Formula Feeding Versions
IMPAACT 1078: Phase IV Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety of Immediate (Antepartum-Initiated) Versus Deferred (Postpartum-Initiated) Isoniazid Preventive Therapy Among HIV-Infected Women in High TB Incidence Settings
Clinical Trial Keywords:
tuberculosis, HIV, PMTCT, breastfeeding, antiretroviral, MDR-TB
Nishi Suryavanshi; Vidya Mave; Nikhil Gupte; Ramesh Bhosale; Pradeep Sambarey; Sandesh Patil; Jayagowri Sastry; Robert Bollinger; Amita Gupta; Anita Shankar. "Contraceptive use and factors associated with postpartum surgical sterilization among HIV-infected women in Pune, India." Journal of HIV/AIDS and Social Services. 2015;14(3):359-370.
Mave V, Chandanwale A, Bhosale R, Shere D, Gupte N, Suryavanshi N, Kulkarni V, Kagal A, Bharadwaj R, Joshi S, Bollinger RC, Gupta A; SWEN (Six Weeks Extended Nevirapine India) and Byramjee-Jeejeebhoy Medical College Clinical Trials Unit Study team. "Vitamin D deficiency and risk of postpartum tuberculosis among HIV-infected breastfeeding mothers in India." Int J Tuberc Lung Dis. 2015 Mar;19(3):302-4. doi: 10.5588/ijtld.14.0658.
Tenforde MW, Gupte N, Dowdy DW, Asmuth DM, Balagopal A, Pollard RB, Sugandhavesa P, Lama JR, Pillay S, Cardoso SW, Pawar J, Santos B, Riviere C, Mwelase N, Kanyama C, Kumwenda J, Hakim JG, Kumarasamy N, Bollinger R, Semba RD, Campbell TB, Gupta A; ACTG PEARLS and NWCS 319 Study Group. "C-reactive protein (CRP), interferon gamma-inducible protein 10 (IP-10), and lipopolysaccharide (LPS) are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settings." PLoS One. 2015 Feb 26;10(2):e0117424. doi: 10.1371/journal.pone.0117424. eCollection 2015.
Havers FP, Detrick B, Cardoso SW, Berendes S, Lama JR, Sugandhavesa P, Mwelase NH, Campbell TB, Gupta A; ACTG A5175 PEARLS and NWCS319 Study Teams. "Change in vitamin D levels occurs early after antiretroviral therapy initiation and depends on treatment regimen in resource-limited settings." PLoS One. 2014 Apr 21;9(4):e95164. doi: 10.1371/journal.pone.0095164. eCollection 2014.
Gupta A, Mathad JS, Yang WT, Singh HK, Gupte N, Mave V, Bharadwaj R, Zaman K, Roy E, Bollinger RC, Bhosale R, Steinhoff MC. "Maternal pneumococcal capsular IgG antibodies and transplacental transfer are low in South Asian HIV-infected mother-infant pairs." Vaccine. 2014 Mar 14;32(13):1466-72. doi: 10.1016/j.vaccine.2014.01.033. Epub 2014 Jan 30.
Savic R, Ruslami R, Hibma J, Hessling A, Ramachandran G, Gamiem AR, Swaminathan S, Mcilleron H, Gupta A, Thakur K, vanCrevel R, Aarnoutse R, Dooley K. Pediatric tuberculous meningitis: model-based approach to determining optimal does of anti-tuberculosis drugs for children. Clin Pharmacol Ther. 2015 Oct 22. doi:10.1002/cpt.202. [Epub ahead of print]
Maddali MV, Dowdy DW, Gupta A, Shah M. Economic and epidemiological impact of early antiretroviral therapy initiation in India. Journal of the International AIDS Society. 2015;18:20217.
Balagopal A, Asmuth DM, Yang W-T, Campbell T, Gupte N, Smeaton L, Kanyama C, Grinsztejn B, Santos B, Supparatpinyo K, Badal-Faesen S, Lama JR, Lalloo U, Zulu F, Pawar JS, Riviere C, Kumarasamy N, Hakim J, Li X-D, Pollard RB, Semba RD, Thomas DL, Bollinger RC, Gupta A. Pre-cART elevation of CRP and CD4+ T-cell immune activation associated with HIV clinical progression in m Multinational case-cohort study. J Acquir Immune Def Syndr 2015 Oct 1.
Hamilton CD, Swaminathan S, Christopher DJ, Ellner J, Gupta A, Sterling TR, Rolla V, Srinivasan S, Karyana M, Siddiqui S, Stoszek SK, Kim P. RePORT International: advancing tuberculosis biomarker research through global collaboration. Clinical Infectious Diseases. 2015;61(suppl 3):S155-S159 doi: 10.1093/cid/civ611.
Podany AT, Bao Y, Swindells S, Chaisson RE, Andersen JW, Mwelase T, Supparatpinyo K, Mohapi L, Gupta A, Benson Cam, Kim P, Fletcher CV on behalf of the ACTG A5279 Study Team. Efavirenz pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for tuberculosis prevention. Clin Infect Dis. 2015;16 Jun. pii: civ464. [Epub ahead of print]
Gandhi BS, Kulkarni K, Godbole M, Dole SS, Kapur S, Satpathy P, Khatri AM, Deshpande PS, Azad F, Gupte N, Bharadwaj R, Bollinger RC, Gupta A. Dengue and chikungunya co-infection associated with more severe clinical disease than mono-infection. International J. of Healthcare and Biomedical Research. 2015 Apr;3(3).
Shivakoti R, Yang WT, Gupte N, Berendes S, Rose A, Cardoso SW, Mwelase N, Kanyama C, Pillay S, Samaneka W, Riviere C, Sugandhavesa P, Santos B, Poongulali S, Tripathy S, Bollinger RC, Currier JS, Tang AM, Semba RD, Christian P, Campbell TB, Gupta A; NWCS 319 and PEARLS Study Team. Concurrent anemia and elevated CRP predicts HIV clinical treatment failure, including TB, post-antiretroviral therapy initiation. Clin Infect Dis. 2015 Mar 31. doi: 10.1093/cid/civ265. [Epub ahead of print]